LTR PHARMA LIMITED ORDINARY (LTP) Short Interest

LTR PHARMA LIMITED ORDINARY (ASX:LTP) had 0.26% of shares reported as short positions as of 5 June 2026, representing 468,707 shares. LTR PHARMA LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).

Short interest
0.26%
Reported positions
468,707
Industry
Pharmaceuticals, Biotechnology & Life Sciences
As of
5 June 2026

Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.

Ltr Pharma logo

LTP

Ltr Pharma

Pharmaceuticals, Biotechnology & Life Sciences

LTR Pharma is an Australian drug development company focused on men's health, specifically commercializing a rapid-onset, on-demand therapeutic nasal spray for erectile dysfunction. Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, aiming for faster action and improved spontaneity compared to existing ED therapies.

pharmaceuticals
biotechnology
men's health
erectile dysfunction

Shorted

short percentage0.26%
reported shorts468.7K
shares on issue181.778M